Chronic rhinosinusitis (CRS) is one of the most common chronic diseases, affecting 14-16% of the US population, resulting in annual direct costs of $4.3 billion and substantially reducing health- related quality of life (QOL) and olfactory function. Due to the chronicity of the disease, and the relatively poor response of many patients to medical treatment, patients with CRS undergo 500,000 surgical procedures annually, with the primary goal of improving QOL. While surgery has been successful for many patients, about 35% are thought to experience a poor surgical outcome. Furthermore, little is known of the medical treatment outcomes for this patient population. Prior studies attempted to relate several patient characteristics to the presence and severity of inflammation as a way to predict outcomes of treatment. While these clinical phenotypes provide some predictive information, data demonstrate heterogeneity even within these clinical phenotype subgroups with regard to severity of inflammation and outcomes of treatment. Work from others and preliminary data have identified important inflammatory markers in the sinonasal mucosa that may provide complementary predictive information to predict outcomes of treatment. However, important questions remain. In order to optimize patient selection for surgery and improve patient counseling on prognosis with medical vs surgical therapy, it is important to determine outcomes in patients treated medically. Another important question is whether mucosal inflammatory markers present at baseline can provide prognostic information that is superior to that provided by patient characteristics and standard diagnostic tests. The studies proposed are hypothesis-testing or hypothesis-generating in nature.
Specific Aim 1 utilizes biostatistical methods to evaluate and reduce bias in comparing disease-specific, general QOL, and olfactory outcomes of patients electing medical treatment of CRS to those electing surgical treatment.
Specific Aim 2 measures cellular, histological, and molecular markers of inflammation in the sinonasal mucosa at baseline in both medical treatment and surgical treatment cohorts and correlates them to baseline clinical measures of CRS disease-severity.
Specific Aim 3 develops comprehensive models of multiple pretreatment factors including sociodemographic, clinical, radiographic, and inflammatory markers to predict disease-specific QOL outcomes of CRS management. Given that an RCT is not possible at this time, these aims will be completed by performing a prospective observational cohort study to evaluate medical vs surgical treatment outcomes of CRS utilizing methods to evaluate and adjust for bias and unmeasured confounders. In addition, novel mucosal markers of inflammation will be measured at baseline and evaluated for their usefulness in predicting treatment outcome.

Public Health Relevance

Chronic rhinosinusitis is one of the most common chronic diseases, which affects 14-16% of the US population and substantially reduces health-related quality of life and olfactory function. It primarily affects the working population, leading to 73 million total restricted activity days per year, annual direct costs of $4.3 billion, and a significant economic burden in the US. This application examines ways to predict who will benefit from medical vs surgical treatment and evaluate the impact on quality of life.

Agency
National Institute of Health (NIH)
Institute
National Institute on Deafness and Other Communication Disorders (NIDCD)
Type
Research Project (R01)
Project #
5R01DC005805-09
Application #
8642616
Study Section
Health Services Organization and Delivery Study Section (HSOD)
Program Officer
Sullivan, Susan L
Project Start
2002-12-01
Project End
2016-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
9
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Otolaryngology
Type
Schools of Medicine
DUNS #
City
Portland
State
OR
Country
United States
Zip Code
97239
Levy, Joshua M; Smith, Timothy L (2017) Is aspirin desensitization indicated for the treatment recalcitrant chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease? Laryngoscope 127:776-777
Smith, Timothy L (2017) THE 2017 13TH ANNUAL DAVID W. KENNEDY, MD, LECTURE The evolution of outcomes in sinus surgery for chronic rhinosinusitis: past, present, and future. Int Forum Allergy Rhinol 7:1121-1126
DeConde, Adam S; Mace, Jess C; Levy, Joshua M et al. (2017) Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope 127:550-555
Teo, Neville W; Mace, Jess C; Smith, Timothy L et al. (2017) Impact of endoscopic sinus surgery on otologic symptoms associated with chronic rhinosinusitis. World J Otorhinolaryngol Head Neck Surg 3:24-31
Cox, Daniel R; Ashby, Shaelene; Mace, Jess C et al. (2017) The pain-depression dyad and the association with sleep dysfunction in chronic rhinosinusitis. Int Forum Allergy Rhinol 7:56-63
Levy, Joshua M; Mace, Jess C; Bodner, Todd E et al. (2017) Defining the minimal clinically important difference for olfactory outcomes in the surgical treatment of chronic rhinosinusitis. Int Forum Allergy Rhinol 7:821-826
Chowdhury, Naweed I; Mace, Jess C; Bodner, Todd E et al. (2017) Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis. Int Forum Allergy Rhinol 7:1149-1155
Levy, Joshua M; Mace, Jess C; Rudmik, Luke et al. (2017) Low 22-item sinonasal outcome test scores in chronic rhinosinusitis: Why do patients seek treatment? Laryngoscope 127:22-28
Alt, Jeremiah A; Thomas, Andrew J; Curtin, Karen et al. (2017) Mortality risk in patients with chronic rhinosinusitis and its association to asthma. Int Forum Allergy Rhinol 7:591-599
Schlosser, R J; Smith, T L; Mace, J et al. (2017) Asthma quality of life and control after sinus surgery in patients with chronic rhinosinusitis. Allergy 72:483-491

Showing the most recent 10 out of 117 publications